Research on the trials that test new treatments in patients. Covers trial design, respiratory and cancer trials, screening tools, and treatment breakthroughs.
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
A video game developed to improve trauma triage decision making in emergency doctors has shown promising results. The game reduced under-triage rates for older patients by 49% compared to those who did not play the game, suggesting improved diagnostic abilities and adherence to guidelines.
A cluster-randomized trial found that an adaptive mobile health intervention effectively reduced the rate of gestational weight gain and total gestational weight gain among pregnant patients with overweight or obesity. The study suggests that technology-based interventions can be a valuable tool in managing excess weight during pregnancy.
A new trial found that proximal hypoglossal nerve stimulation (pHGNS) significantly reduced breathing interruptions during sleep and improved daytime sleepiness without adverse events. The therapy, an FDA-approved alternative to nasal positive airway pressure, was found to be safe and effective in patients with moderate-to-severe obstr...
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
The Phase I MYTHIC trial demonstrated a strong synergy between zedoresertib and lunresertib, showing durable regressions and consistent tumor shrinkage in patients with ovarian cancer. The combination achieved an overall disease control rate of 68.5% and a molecular response rate of 47%.
A first-in-human trial shows that an infusion of immune cells derived from a donor's blood can prime the recipient's immune system to accept a donor liver, potentially reducing lifelong immunosuppression. Eight out of 13 participants achieved complete withdrawal of immunosuppression and remained off for more than three years.
The JAMA+ Trials platform provides a comprehensive online space for clinical trial research, featuring multimedia content and tailored resources. Recent trials published across multiple JAMA Network journals are highlighted on the platform.
The hospital is conducting a phase 2 clinical trial evaluating STAR0602, which activates the immune system to stop tumor growth across various cancers. The goal of this study is to identify safer and more effective treatments for people with advanced cancers.
A phase 2 clinical trial shows that a new drug, elraglusib, when combined with chemotherapy, doubles one-year survival rates in pancreatic cancer patients, reducing the risk of death by 38%. The study is a rare success in showing a survival benefit applicable to a broad population.
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
A new multicenter trial demonstrates that hepatologists trained in palliative care can deliver the same quality-of-life benefits as a palliative care specialist. Quality of life improved significantly in both groups, with symptom burden and short-term mortality comparable between groups.
A new clinical trial at the University of Cincinnati is testing a peptide solution to treat prosthetic joint infections after total knee replacement. The trial aims to reduce the need for repeat surgeries and expand the treatment window beyond two weeks.
A phase 2 clinical trial shows that mezagitamab can effectively increase platelet counts in patients with immune thrombocytopenia, improving quality of life. The investigational medication has a rapid effect, normalizing platelet counts in 48 hours.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.
A phase 1/2 clinical study found that pralsetinib improved durable responses with manageable safety profiles in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer. The overall response rate was 78% and median duration of response was longer in patients with the CCDC6-RET fusion gene.
A phase III clinical trial established a new treatment standard for patients with stage III colon cancer and deficient DNA mismatch repair. Immunotherapy drug atezolizumab showed significant benefits when added to chemotherapy, lowering the risk of cancer recurrence by 50%.
A nationwide Japanese trial found that catheter ablation did not reduce the risk of recurrent stroke or major cardiovascular events in patients with atrial fibrillation who had recently experienced a stroke. The study, which enrolled 251 patients and followed them for over three years, suggests that routine addition of catheter ablatio...
Dr. Roxana Mehran was appointed President of the American College of Cardiology, focusing on innovation, equity, and global collaboration to advance cardiovascular care. She aims to improve heart health for all through partnerships with major organizations.
A multicenter study found that red blood cell exchange transfusion significantly improves clinical outcomes for patients hospitalized with severe babesiosis, a potentially life-threatening tick-borne infection. The procedure was associated with substantially lower risk of in-hospital death or readmission.
Early and continuous acoramidis treatment resulted in sustained incremental reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization. The findings support the importance of early and continuous long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy.
Researchers found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide reported improved emotional responses and a greater quality of life. The study suggests that tirzepatide may offer broader benefits beyond glucose control, improving patients' physical and emotional well-being.
A new study shows that PSMA therapy can delay the need for hormone therapy in prostate cancer patients by an average of 20 months. The therapy is effective in earlier stages of the disease, improving survival and quality of life for approximately two out of three patients.
Extended low-dose apixaban effectively reduced symptomatic superficial vein thrombosis (SuVT) risk. Patients with enduring risk factors for SuVT benefited from this anticoagulation strategy.
A global clinical trial led by SickKids has found that mavacamten improves blood flow and reduces obstruction in youth with hypertrophic cardiomyopathy (HCM), a genetic heart disease. The study's results offer hope to families avoiding open-heart surgery, setting the stage for precision therapeutics.
The Emboliner device performed comparably to the Sentinel device in protecting against stroke and death in patients undergoing TAVR. The study found that both devices captured similar amounts of debris particles, with the Emboliner capturing three times as many larger particles.
A minimally invasive procedure using a clip to repair the valve significantly reduced heart failure hospitalizations by 40% in patients with severe tricuspid regurgitation. The study, presented at the American College of Cardiology's Annual Scientific Session, showed improved long-term outcomes without crossover between treatment groups.
The EMPEROR-Preserved risk model demonstrated good performance in the FINEARTS-HF trial, showing that baseline risk does not modify the relative treatment effect of finerenone. Finerenone has been shown to have a significant benefit for heart failure patients.
A post hoc analysis of the Finerenone Trial reveals that sudden death in heart failure was often preceded by modest worsening of symptoms and declining quality of life. The study suggests limited specificity for sudden death among other modes of death, implying a complex trajectory before modes of death.
A clinical trial found that intensive cholesterol-lowering therapy reduced the risk of cardiovascular events by 31% in high-risk patients with diabetes. The treatment, evolocumab, lowered LDL-C levels by approximately 60%, and was well-tolerated.
The FDA has approved a gene therapy for severe leukocyte adhesion deficiency-I, a rare genetic condition that affects one in a million children globally. The therapy, Kresladi, has been shown to significantly reduce severe infections and improve immune function in treated patients.
Dr. Emily Lukacz has been named the 2026 President of American Urogynecologic Society, a prestigious position that recognizes her innovative leadership in the complex field of urogynecology. As president, she aims to streamline treatment by educating primary care providers and allied health professionals.
The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.
A multi-phase clinical study will examine dosing, safety and long-term effects of rapamycin in older adults to guide future research on extending health span. Researchers aim to establish evidence-based guidance for the drug's use and move beyond speculation.
A global panel of experts recommends a 10-year trial with 5,000 participants at high risk of cancer due to pre-cursor conditions. The trial will evaluate the potential efficacy of GLP-1 and dual receptor agonists in preventing obesity-related cancers.
The Linda and Mike Mussallem Foundation has donated to USC's Keck School of Medicine to enhance clinical trials for individuals with Down syndrome at risk for Alzheimer's. This will increase domestic and international sites, accelerating the development of treatments specifically for this population.
A new Australian study shows that a tailored, home-based program can significantly reduce the number of falls after stroke. The 'falls after stroke trial' (FAST) found that the program reduced falls by 33% over 12 months.
A multicenter randomized clinical trial found no significant differences in cognitive improvement between exercise, intensive pharmacological reduction of cardiovascular risk factors, or both in older adults. The study results challenge current recommendations on lifestyle modifications for dementia prevention.
Southwest Research Institute's new facility supports pharmaceutical development, bioengineering research, and streamlined clinical supply production. The facility enhances regulatory efficiency, quality systems, and communication between scientists.
The largest behavioral study on kidney stone prevention tested a hydration program with Bluetooth-enabled smart water bottles and personalized hydration goals. While participants did hydrate more, the increase wasn't large enough to lower symptomatic kidney stone recurrence across the group.
Dr. Ludwig Kappos has made enormous contributions to MS research, advancing clinical trial conduct and outcome measures, and leading international collaborations. He will formally receive the award at the American Academy of Neurology Annual Meeting in Chicago on April 19, 2026.
The ECOG-ACRIN Cancer Research Group has completed enrollment of 600 patients in the phase 2/3 trial EA6141, evaluating dual checkpoint blockade with nivolumab and ipilimumab plus sargramostim for unresectable stage 3 or 4 melanoma. The trial aims to assess overall survival, progression-free survival, and treatment tolerability.
The Robert A. Winn Excellence in Clinical Trials Award Program is expanding its career development award to include neuropsychiatry researcher-physicians. This expansion aims to improve clinical trial enrollment and represent diverse patient populations affected by complex disorders.
A randomized clinical trial investigated the effectiveness of low-use vs high-use physical restraint strategies in critically ill patients receiving mechanical ventilation in the ICU. The study found no significant reduction in days free of delirium or coma at 14 days, regardless of the restraint strategy used.
Researchers at Université catholique de Louvain discovered a bacterium, Dolosigranulum pigrum, that reduces the persistence of symptoms characteristic of long Covid. The study found that this bacterium is associated with improved recovery following viral respiratory infections.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A clinical trial found that weekly injectable extended-release buprenorphine treatment resulted in higher rates of illicit opioid abstinence during pregnancy compared to sublingual buprenorphine. Serious adverse events were also less common in the extended-release group.
Continuing GLP-1/GIP agonists before upper endoscopy increased clinically significant residual gastric volume, but did not elevate adverse event risk. Clear liquids the day prior to the procedure may mitigate this risk.
A new smartphone app has been shown to significantly improve sex life and delay ejaculation in men with premature ejaculation. The app, developed by urologists and psychologists, teaches men therapeutic techniques and exercises to manage arousal and control ejaculation.
Researchers evaluated 12 hypnotic medications on sleep architecture and respiratory function in adults with obstructive sleep apnea. The study found that while some medications worsened respiratory outcomes, others showed no significant effects, highlighting the need for individualized treatment.
The ISSCR has launched a new continuing education course on stem cell therapies for Parkinson’s disease, addressing the need for clinicians to provide accurate information on emerging treatments. The course features expert faculty and patient perspectives, and is available through a free and paid pathway.
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
A new study suggests that using virtual reality (VR) to explain medical procedures can help patients better understand their treatment and reduce anxiety. The research tested VR as part of the consent process for a procedure to treat kidney stones, with patients reporting improved understanding and reduced anxiety after the experience.
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
Genethon's GNT0004 gene therapy shows long-term efficacy in patients with Duchenne muscular dystrophy, maintaining clinical efficacy and safety at two years. The trial included 72 boys aged 6-10 with retained walking ability, treated with GNT0004 at a therapeutic dose.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
The Butantan-DV dengue vaccine, developed in Brazil, shows 80.5% effectiveness against severe cases over five years, with no hospitalizations in the vaccinated group. The vaccine was 65% effective in preventing symptomatic dengue during the five-year monitoring period.
A large venous thrombosis trial has found that apixaban is safer than rivaroxaban, with 3.3% of participants experiencing clinically relevant bleeding compared to 7.1% with rivaroxaban. This trial has significant implications for clinical practice and patient care.